PulmoSIM Therapeutics Granted Orphan Drug Designation for PT001 by the FDA to Treat Pulmonary Arterial Hypertension

SAN FRANCISCO--(BUSINESS WIRE)-- #PAH--PulmoSIM Therapeutics (PulmoSIM), the pharmaceutical subsidiary of VeriSIM Life, Inc., is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for asset PT001 for the treatment of Pulmonary Arterial Hypertension (PAH). PT001 targets multiple responsible pathways in PAH, to provide...

Click to view original post